NCT00479336已完成2 期
A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 104
- 主要终点
- Body Weight (Amount of Change)
研究概览
简要总结
To investigate the dose response for changes from baseline in body weight as a primary endpoint and to investigate improvement in ascites, abdominal circumference, lower-limb edema, and pleural effusion as secondary endpoints in seven-day repeated oral administration of OPC-41061 at 7.5, 15, and 30 mg/day or placebo in cirrhosis patients with ascites despite taking conventional diuretics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with ascites despite taking either of the following combinations of loop diuretics and an anti-aldosterone agent (spironolactone) for at least 7 days prior to start of the study drug administration.
- •Combination 1: Loop diuretics at indicated below in combination with an anti-aldosterone agent at a daily dose of 25 mg or more
- •Furosemide: 40 mg/day or more
- •Other loop diuretic: a daily dosage equivalent to 40 mg or more of furosemide Bumetanide: 1 mg/day or more, Piretanide: 6 mg/day or more, Azosemide: 60 mg/day or more, Torasemide: 8 mg/day or more Combination 2: Anti-aldosterone agent at a daily dose of 50 mg or more in combination with furosemide at a daily dose of 20 mg or more (or one of the other loop diuretics specified in Combination 1 at a daily dosage equivalent to 20 mg or more of furosemide)
- •Patients who have been hospitalized or are able to stay at the study site from the start of the run-in observation period until completion of postdosing observation
- •Subjects capable of giving informed consent to participate in the study of their own free will.
排除标准
- •Subjects with any of the following complications or symptoms: (1) Hepatic encephalopathy (Hepatic coma grade: II or more), (2) Poorly-controlled hepatocellular carcinoma (i.e., hepatocellular carcinoma with vessel infiltration confirmed by imaging in the main trunk or main branch of the portal vein, inferior vena cava, or the main trunk of the hepatic vein), (3)Endoscopic findings within 30 days prior to screening examination requiring new therapy for esophageal and gastric varicose vein during the study period, (4)Repeated haemorrhoidal bleeding due to rectal varicose vein within 30 days prior to screening examination, (5)Diabetes mellitus with poorly controlled blood glucose, (6)Heart failure (NYHA class III or IV), (7)Anuria, (8)Impairment of urination due to urinary tract stricture, urinary calculus, tumor in the urinary tract, or other cause
- •Subjects with a history of any of the following diseases: (1) Cerebrovascular disorder within 30 days prior to the screening examination, (2)Episode of gout within 90 days prior to the screening examination, (3)Hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
- •Subjects who are obese (body mass index [BMI, body weight (kg)/height (m)2] exceeding 35)
- •Patients with supine systolic blood pressure exceeding 90 mmHg
- •Subjects with any of following abnormal laboratory values: hemoglobin exceeding 8.0 g/dL, total bilirubin exceeding 3.0 mg/dL, serum creatinine exceeding 3.0 mg/dL, serum sodium exceeding 147 mEq/L, serum potassium exceeding 5.5 mEq/L, or uric acid exceeding 8.0 mg/dL
- •Patients who are unable to take oral medication
- •Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant
- •Subjects who received blood products, including albumins, within 7 days prior to the screening examination
- •Subjects who received any investigational drug other than OPC-41061 within 30 days prior to the screening examination
- •Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061
- •Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
研究组 & 干预措施
1
Placebo Comparator
干预措施: OPC-41061 placebo (Drug)
2
Experimental
干预措施: OPC-41061 7.5mg (Drug)
3
Experimental
干预措施: OPC-41061 15mg (Drug)
4
Experimental
干预措施: OPC-41601 30mg (Drug)
结局指标
主要结局
Body Weight (Amount of Change)
时间窗: Baseline, Day 7 or at the discontied of treatment
Changes in body wight from baseline at the final timepoint (LOCF). A linear regression model using changes in body weight from baseline at the final timepoint as the criterion variable and dose as the explanatory variable was fitted to the dataset.
次要结局
- Abdominal Circumference(Baseline, Day 7 or at the discontied of treatment)
研究者
相似试验
未知
2 期
A dose-defining study of OPC-41061 in treatment of hepatic edemaJPRN-jRCT2080220392Otsuka Pharmaceutical Co., Ltd.
已完成
2 期
Japanese Dose-Response Study of Rimonabant in Obese PatientsObesityNCT00459004Sanofi527
已完成
2 期
OC000459 Dose Finding Study in Hay Fever Sufferers.Allergic RhinitisNCT00697281Oxagen Ltd120
已完成
2 期
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & AnemiaAnemiaCongestive Heart FailureNCT00086086Amgen150
已完成
4 期
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With ObesityAdolescent ObesityObesity in AdolescenceAdolescent OverweightNCT03922945VIVUS LLC223